Advertisement

Future Directions

  • Brian V. Reamy
Chapter

Introduction

The past decades have seen evidence accumulate in favor of ever lower LDL cholesterol goals. Some worry that there is a point at which the harm of a low LDL may overtake the benefits. Additionally, newer agents are needed to help achieve these low levels of LDL and to help raise HDL. This chapter reviews some of the trends and future directions in the management of hyperlipidemia.

How Low Do You Go?

The Heart Protection Study showed that, regardless of the effect on lipid levels, statin therapy has benefits in all patients with known disease and in those patients at high risk who do not as yet have clinical manifestations of atherosclerotic vascular disease [1]. Other studies such as the PROSPER Trial also suggested the benefits of statin therapy in primary and secondary prevention regardless of the effect on lipid levels. Several investigators began to suggest that we should abandon the concept of titrating the intensity of our treatment to achieve a specific LDL level...

Keywords

Familial Hypercholesterolemia Microsomal Triglyceride Transfer Protein Behavioral Health Provider High Dose Statin Therapy Transfer Protein Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of Cholesterol Lowering in 20,536 high-risk individuals: a randomized placebo controlled trial. Lancet 2002;360:7–22.Google Scholar
  2. 2.
    Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction. IDEAL study: a randomized controlled trial. JAMA 2005;294:2437–2445.PubMedCrossRefGoogle Scholar
  3. 3.
    Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA). Lancet 2003;361:1149–1158.PubMedCrossRefGoogle Scholar
  4. 4.
    LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425–1435.PubMedCrossRefGoogle Scholar
  5. 5.
    Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495–1504.PubMedCrossRefGoogle Scholar
  6. 6.
    Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48:438–445.PubMedCrossRefGoogle Scholar
  7. 7.
    Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007;356:148–156.PubMedCrossRefGoogle Scholar
  8. 8.
    Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419–1423.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Chair and Associate Professor, Department of Family Medicine, Uniformed ServicesUniversity of the Health SciencesMaryland

Personalised recommendations